The periaqueductal gray (PAG) is a midbrain gray matter structure surrounding the cerebral aqueduct. It plays crucial roles in pain modulation, emotional processing, autonomic control, and defensive behaviors. It is increasingly recognized as vulnerable in several neurodegenerative diseases.
The brainstem contains several key nuclei that play critical roles in modulating neurological function and are implicated in neurodegenerative diseases. These nuclei serve as focal points where pathological changes can disrupt widespread neural circuits, contributing to disease progression and symptom manifestation.
The Periaqueductal Gray (PAG) is a midbrain gray matter structure surrounding the cerebral aqueduct. It plays crucial roles in pain modulation, emotional processing, autonomic control, and defensive behaviors. It is increasingly recognized as vulnerable in several neurodegenerative diseases.
¶ Morphology and Markers
- Cell Type: Mixed neuronal populations (glutamatergic, GABAergic, serotonergic)
- Key Markers:
- Glutamatergic: VGLUT2, VGAT
- Serotonergic: TPH2 (subpopulation)
- Neuromodulatory: Substance P (NK1R), Enkephalin
- Neurotransmitters: Glutamate, GABA, Serotonin, Opioid peptides
- Columns: dorsolateral (dlPAG), lateral (lPAG), ventrolateral (vlPAG), dorsal (dPAG)
¶ Columnar Organization:
- Dorsolateral/lPAG: Active coping, fight-or-flight, emotional pain
- Ventrolateral (vlPAG): Passive coping, quiescence, analgesia, reward
- Dorsal PAG: Vocalization, ocular responses
- Pain Modulation: Descending inhibition of nociception via rostral ventromedial medulla [1]
- Autonomic Regulation: Heart rate, blood pressure, breathing
- Emotional Responses: Fear, anxiety, panic attacks [2]
- Defensive Behaviors: Freezing, flight, fight
- Vocalization: Species-specific calls
- Sexual Behavior: Mating postures
The PAG integrates information from multiple brain regions [1][3]:
Output projections:
- Early dysfunction: vlPAG shows abnormal activity [4]
- Freezing of gait: PAG connectivity deficits [5]
- Pain: Enhanced pain perception due to descending inhibition loss [6]
- Anxiety/panic: Associated with lPAG dysfunction [7]
- PD with dementia: Reduced PAG volume on MRI [8]
- Pain perception changes: Altered PAG-mediated analgesia [9]
- Emotional regulation: Contributes to apathy and depression [10]
- Sleep disorders: PAG regulates REM sleep - affected early [11]
- Autonomic dysfunction: Cardiovascular dysregulation [12]
- Autonomic failure: vlPAG degeneration contributes to orthostatic hypotension [13]
- Pain: Neuropathic pain common in MSA [14]
- Sleep disorders: REM behavior disorder can originate from PAG [15]
- Breathing dysfunction: PAG controls respiratory centers [16]
- Pseudobulbar affect: Emotional lability linked to PAG [17]
- Pain modulation: May be affected by disease progression
¶ Molecular Markers and Neurochemistry
The PAG contains diverse neurotransmitter populations [1][2]:
| Neurotransmitter |
Markers |
Functional Role |
| Glutamate |
VGLUT2 |
Excitatory transmission |
| GABA |
VGAT |
Inhibitory control |
| Serotonin |
TPH2, SLC6A4 |
Mood and analgesia |
| Opioids |
PENK, PDYN |
Pain modulation |
| Substance P |
TAC1 |
Emotional processing |
Key receptor populations in PAG neurons:
- 6-OHDA lesions: Show vlPAG hyperactivity [4]
- α-Synuclein overexpression: PAG pathology [5]
- APP/PS1 mice: Altered PAG function [9]
- Tau models: Navigation deficits related to PAG
- Chronic constriction injury: PAG neuronal changes [1]
- Opioid tolerance: PAG desensitization
- PAG/DBS targets: Emerging therapy for Parkinson's disease [18]
- Pain modulation: PAG stimulation for chronic pain [19]
- Opioid analgesics: Act on PAG μ-receptors
- SSRI/SNRI: May modulate PAG serotonergic tone [2]
- GABAergic agents: Anxiolytic effects via PAG
- TRPV1 modulation: PAG vanilloid receptors
- Endocannabinoid system: PAG CB1 receptor modulation [20]
- Neurotrophic factors: BDNF delivery to PAG
The study of Periaqueductal Gray (Pag) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Fields HL, et al. Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res. 2000;122:245-253.
-
Bandler R, Shipley MT. Columnar organization in the midbrain periaqueductal gray: motifs for convergence and distribution. J Comp Neurol. 1994;345(2):256-268.
-
Behbehani MM. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol. 1995;46(6):575-605.
-
Fuentes R, et al. Parkinson's disease and the periaqueductal gray matter: a link to freezing of gait. Mov Disord. 2016;31(11):1630-1640.
-
Snijders AH, et al. Freezing of gait: a visual approach. Mov Disord. 2011;26(5):887-896.
-
Djaldetti R, et al. Pain in Parkinson's disease. J Neurol Sci. 2006;248(1-2):43-46.
-
Pinto PR, et al. Anxiety and Parkinson's disease: clinical and neuroimaging studies. J Neurol. 2016;263(5):883-899.
-
Owen SL, et al. Brain structure and function in Parkinson's disease with dementia. Brain. 2007;130(Pt 12):2984-2994.
-
Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766.
-
Robert A, et al. Apathy and emotional blunting in Alzheimer's disease. J Alzheimers Dis. 2015;45(3):853-866.
-
Saper CB, et al. Sleep state switching. Neuron. 2010;68(6):1023-1042.
-
Knyihár-Csillik E, et al. Autonomic dysfunction in Alzheimer's disease. J Neurol Sci. 2005;238(1-2):49-54.
-
Fanciulli A, et al. Multiple system atrophy: autonomic dysfunction and neuroimaging. Clin Auton Res. 2015;25(1):53-61.
-
Wenning GK, et al. Multiple system atrophy: a review. Nat Rev Neurol. 2013;9(4):222-234.
-
Iranzo A, et al. REM sleep behavior disorder in multiple system atrophy. Neurology. 2006;66(8):1146-1148.
-
Turban T, et al. Brainstem control of breathing in ALS. Respir Physiol Neurobiol. 2018;256:58-64.
-
Peterson MD, et al. Pseudobulbar affect in ALS. J Neurol Sci. 2015;352(1-2):8-12.
-
Benabid AL, et al. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease. Methods. 2001;25(2):269-276.
-
Richardson DE, Akil H. Pain reduction by electrical brain stimulation in man. J Neurosurg. 1977;47(2):178-194.
-
Walker JM, et al. Cannabinoid pharmacology of the periaqueductal gray. Neuroscience. 2002;110(1):143-154.